NSD3 (2E9): sc-130009



The Power to Question

BACKGROUND

The deduced 1,437 amino acid NSD3 protein contains two PWWP domains involved in protein-protein interactions, five PHD-type zinc finger motifs found in chromatin-associated proteins, a SAC (SET-associated cys-rich) domain, a SET domain and a C-terminal C5HCH domain. Two NSD3 variants have been identified. The short variant comprised of 645 amino acids, arises from alternative polyadenylation and exon splicing and contains a single PWWP domain. A longer NSD3 variant, which is only expressed in HeLa cells, is comprised of 1,388 amino acid residues. The human WHSC1L1 gene, which encodes the NSD3 protein, shares 68% and 55% identity with mouse Nsd1 and human WHSC1, respectively. Highest expression of NSD3 is observed in brain, heart and skeletal muscle tissues; lower levels of NSD3 expression are observed in the liver and lungs.

REFERENCES

- Angrand, P.O., Apiou, F., Stewart, A.F., Dutrillaux, B., Losson, R. and Chambon, P. 2001. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 74: 79-88.
- Stec, I., van Ommen, G.J. and den Dunnen, J.T. 2001. WHSC1L1, on human chromosome 8p11.2, closely resembles WHSC1 and maps to a duplicated region shared with 4p16.3. Genomics 76: 5-8.
- 3. Rosati, R., La Starza, R., Veronese, A., Aventin, A., Schwienbacher, C., Vallespi, T., Negrini, M., Martelli, M.F. and Mecucci, C. 2002. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99: 3857-3860.
- Douglas, J., Coleman, K., Tatton-Brown, K., Hughes, H.E., Temple, I.K., Cole, T.R., Rahman, N. and Childhood Overgrowth Collaboration. 2005. Evaluation of NSD2 and NSD3 in overgrowth syndromes. Eur. J. Hum. Genet. 13: 150-153.
- Tonon, G., Wong, K.K., Maulik, G., Brennan, C., Feng, B., Zhang, Y., Khatry, D.B., Protopopov, A., You, M.J., Aguirre, A.J., Martin, E.S., Yang, Z., Ji, H., Chin, L. and Depinho, R.A. 2005. High-resolution genomic profiles of human lung cancer. Proc. Natl. Acad. Sci. USA 102: 9625-9630.

CHROMOSOMAL LOCATION

Genetic locus: WHSC1L1 (human) mapping to 8p11.23.

SOURCE

NSD3 (2E9) is a mouse monoclonal antibody raised against amino acids 383-660 of recombinant NSD3 of human origin.

PRODUCT

Each vial contains 50 $\mu g \; lg G_{2b}$ in 500 μl PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS


NSD3 (2E9) is recommended for detection of NSD3 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000)


Suitable for use as control antibody for NSD3 siRNA (h): sc-61235, NSD3 shRNA Plasmid (h): sc-61235-SH and NSD3 shRNA (h) Lentiviral Particles: sc-61235-V.

Molecular Weight of NSD3 isoforms 1-4: 162/156/73/155 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200 or MCF7 nuclear extract: sc-2149.

DATA





NSD3 (2E9): sc-130009. Western blot analysis of NSD3

NSD3 (2E9): sc-130009. Western blot analysis of NSD3 expression in HeLa whole cell lysate.

SELECT PRODUCT CITATIONS

 Dutt, A., Ramos, A.H., Hammerman, P.S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K.E., Stransky, N., Greulich, H., Gray, N.S. and Meyerson, M. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 6: e20351.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com